AZD2936

DRUG5 trials

Sponsors

AstraZeneca, University Health Network, Toronto

Conditions

Advanced or Metastatic NSCLCEsophageal AdenocarcinomaGastric CancerGastro-esophageal Junction CancerLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)Metastatic Non-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung CarcinomaPancreatic Ductal Adenocarcinoma

Phase 1

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Active, not recruitingNCT03819465

AstraZenecaMetastatic Non-Small Cell Lung Cancer (NSCLC)

Start: 2018-12-27End: 2026-07-01Updated: 2026-05-12

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruitingNCT04612751

AstraZenecaAdvanced or Metastatic NSCLC

Start: 2021-02-02End: 2027-05-04Updated: 2026-10-27

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Active, not recruitingNCT04995523

AstraZenecaNon-Small-Cell Lung Carcinoma

Start: 2021-09-14End: 2028-06-01Updated: 2026-07-14

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

RecruitingNCT06005493

AstraZenecaEsophageal Adenocarcinoma, Gastric Cancer, Gastro-esophageal Junction Cancer +1

Start: 2023-07-11End: 2029-03-16Target: 392Updated: 2026-09-25

Phase 2

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

RecruitingNCT05414032

University Health Network, TorontoLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

Start: 2023-07-12End: 2028-07-01Target: 102Updated: 2026-10-05

Related Papers

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study

Clinical Cancer Research2026-08-10

Abstract CT173: Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): The MERIDIAN Phase II trial

Cancer Research2026-04-17

Abstract 5546: Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC

Cancer Research2026-04-03

MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.

2025-11-07

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release

Journal for ImmunoTherapy of Cancer2025-08-01

First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).

Journal of Clinical Oncology2025-05-285 citations

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

Future Oncology2024-10-2911 citations

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.

Journal of Clinical Oncology2023-06-0117 citations

TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2023-06-0110 citations

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Cancer Immunology Immunotherapy2023-04-0589 citations

469 Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT

Regular and Young Investigator Award Abstracts2022-11-016 citations